ACVC Premium Access

Pre-treatment with P2Y12 inhibitors in ACS is unnecessary and risky – Discussion.

Congress Presentation

5 more presentations in this session

Pre-treatment with P2Y12 inhibitors in ACS is unnecessary and risky – PRO.

Speaker: Professor K. Huber (Vienna, AT)

Thumbnail

Pre-treatment with P2Y12 inhibitors in ACS is unnecessary and risky – CON.

Speaker: Professor C. Granger (Durham, US)

Thumbnail

Prasugrel and ticagrelor are equal in PCI for NSTEMI and STEMI - PRO.

Speaker: Professor R. Welsh (Edmonton, CA)

Thumbnail

Prasugrel and ticagrelor are equal in PCI for NSTEMI and STEMI - CON.

Speaker: Professor A. Kastrati (Munich, DE)

Thumbnail

Prasugrel and ticagrelor are equal in PCI for NSTEMI and STEMI - Discussion.

Thumbnail

Access the full session

Debating Oral P2Y12 inhibitors Use – are there differences across the Atlantic?

Speakers: Professor K. Huber, Professor C. Granger, Professor R. Welsh, Professor A. Kastrati
Thumbnail

About the event

Image

ACVC 2021

13 March - 14 March 2021

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk